Persistent CML-initiating cells, or CML stem cells, which are protected from imatinib killing by their quiescent status, are
probably responsible for the regrowth of the disease.
See under Newswire for PDF of this very interesting article by Emmanuelle Passegué & Patricia Ernst in current issue of Nature Medicine
My thanks to Giora Sharf for sending me a copy.
Sandy